Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to give written consent to take part in the study
- People who have a confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis (a condition where a specific protein builds up and damages organs)
- People who are 18 years of age or older at the time of signing the consent form
- People who are willing and able to complete electronic health questionnaires as part of the study
Who may not be able to join:
- People who are currently taking part in another clinical trial for ATTR amyloidosis
- People who were involved in planning or running this study
- People who have a different type of amyloidosis, specifically primary (AL) amyloidosis or serum protein A (AA) amyloidosis, rather than the ATTR type
- People who have ATTR amyloidosis but have no symptoms, or who carry the genetic mutation linked to ATTR amyloidosis but have not developed the condition
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Demographic characteristics (overall and in patients initiating a treatment with eplontersen); Treatment patterns (overall and in patients initiating a treatment with eplontersen); Clinical characteristics (overall and in patients initiating a treatment with eplontersen); Findings from biopsy (overall and in patients initiating a treatment with eplontersen); Findings from Cardiovascular magnetic resonance imaging (CMR) (overall and in patients initiating a treatment with eplontersen); Findings from Bone tracer cardiac scintigraphy (overall and in patients initiating a treatment with eplonterse...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.